Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis  by Hu, Xinyang et al.
Hu et al Cardiopulmonary Support and PhysiologyTransplantation of hypoxia-preconditioned
mesenchymal stem cells improves infarcted heart
function via enhanced survival of implanted cells and
angiogenesis
Xinyang Hu, MD,a,c Shan Ping Yu, MD, PhD,c,d Jamie L. Fraser, BA,c Zhongyang Lu, MD, PhD,c Molly E. Ogle, BS,c
Jian-An Wang, MD, PhD,b and Ling Wei, MDcCS
PObjectives: This study explored the novel strategy of hypoxic preconditioning of
bone marrow mesenchymal stem cells before transplantation into the infarcted heart
to promote their survival and therapeutic potential of mesenchymal stem cell trans-
plantation after myocardial ischemia.
Methods: Mesenchymal stem cells from green fluorescent protein transgenic mice
were cultured under normoxic or hypoxic (0.5% oxygen for 24 hours) conditions. Ex-
pression of growth factors and anti-apoptotic genes were examined by immunoblot.
Normoxic or hypoxic stem cells were intramyocardially injected into the peri-infarct
region of rats 30 minutes after permanent myocaridal infarction. Death of mesenchy-
mal stem cells was assessed in vitro and in vivo after transplantation. Angiogenesis,
infarct size, and heart function were measured 6 weeks after transplantation.
Results: Hypoxic preconditioning increased expression of pro-survival and pro-
angiogenic factors including hypoxia-inducible factor 1, angiopoietin-1, vascular en-
dothelial growth factor and its receptor, Flk-1, erythropoietin, Bcl-2, and Bcl-xL. Cell
death of hypoxic stem cells and caspase-3 activation in these cells were significantly
lower compared with that in normoxic stem cells both in vitro and in vivo. Transplan-
tation of hypoxic versus normoxic mesenchymal stem cells after myocardial infarc-
tiion resulted in an increase in angiogenesis, as well as enhanced morphologic and
functional benefits of stem cell therapy.
Conclusions: Hypoxic preconditioning enhances the capacity of mesenchymal stem
cells to repair infarcted myocardium, attributable to reduced cell death and apoptosis
of implanted cells, increased angiogenesis/vascularization, and paracrine effects.
M
yocardial infarction (MI) induces the irreversible loss of cardiomyocytes,
scar formation, and may ultimately result in congestive heart failure.1
Bone marrow mesenchymal stem cells (MSCs) are multipotent adult
stem cells2 and able to differentiate into endothelial cells, vascular smooth muscle
cells, and perhaps even cardiac-like myocytes when transplanted into the ischemic
heart.3 Both animal and clinical studies have provided evidence that MSC transplan-
tation can improve cardiac function through possible myogenesis and angiogenesis
after MI.4,5 Some studies, however, have failed to observe the therapeutic effects of
MSC transplantation6,7; thus, there is a need for further investigation into the use of
MSCs and the improvement of transplantation techniques after MI.
A major dilemma in stem cell therapy for ischemic heart diseases is the low sur-
vival of transplanted cells in the ischemic and peri-infarcted region.6,8 Most implanted
cells may die within 4 days after transplantation into the ischemic heart.9 Endogenous
and environmental factors, such as the inflammatory response, may contribute to cell
death. Thus, improving grafted cell survival after transplantation is critical for enhanc-
ing the efficacy and efficiency of stem cell therapy.
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CSPAbbreviations and Acronyms
dp/dt 5 rate of pressure rise
EPO 5 erythropoietin
EPOR 5 cognate receptor of erythropoietin
GFP 5 green fluorescent protein
HIF-1a 5 hypoxia-inducible factor-1a
H-MSC 5 hypoxic mesenchymal stem cell
HP 5 hypoxic preconditioning
LVEDP 5 left ventricular end-diastolic pressure
LVSP 5 left ventricular systolic pressure
MI 5 myocardial infarction
MSC 5 mesenchymal stem cell
N-MSC 5 normoxic mesenchymal stem cell
PBS 5 phosphate-buffered saline solution
TUNEL 5 terminal deoxynucleotidyl transferase
biotin-dUPT nick end labeling
VEGF 5 vascular endothelial growth factor
Angiogenesis remains one of the putative mechanisms in
cardiac functional recovery after MI and stem cell transplan-
tation.10 Stimulating angiogenesis showed therapeutic effects
in ischemic heart disease.11 Transplanted MSCs can stimu-
late angiogenesis after MI by secreting multiple angiogenic
cytokines and differentiating into endothelial cells.12 It can
be reasoned that enhancing the MSC’s ability to promote
angiogenesis will further increase the therapeutic potential
of MSC transplantation after MI.
Hypoxic preconditioning (HP) by sublethal hypoxic insult
stimulates endogenous mechanisms resulting in multiple
responses including protein expressions that protect against fu-
ture lethal hypoxia and other insults. HP can decrease apoptosis
of neurons through induction of hypoxia-inducible factor-1a
(HIF-1a)13 and protect myocytes from hypoxia and reperfu-
sion injury.14 HP stimulates myocardial angiogenesis to an ex-
tent sufficient to exert significant cardioprotection after MI.15
Cell transplantation therapy and HP have been studied as
separate research topics. We16 recently demonstrated that in
vitro HP of embryonic stem cells significantly increased their
survival and tissue repair capabilities after transplantation
into the ischemic brain. On the basis of the well-documented
manifold benefits of HP, we examined the hypothesis that HP
of cultured MSCs would promote their survival in vitro as
well as after transplantation. Furthermore, enhanced survival
and trophic support would contribute to endothelial differen-
tiation and stimulate angiogenesis. The HP strategy for stem
cell transplantation would ultimately benefit functional
recovery after MI.
Materials and Methods
MSC Culture
Bone marrow MSCs were isolated and harvested as previously
described.17 In brief, MSCs were acquired from the femoral and tib-
ial bones of green fluorescent protein (GFP) transgenic mice. MSCs800 The Journal of Thoracic and Cardiovascular Surgery c Aprwere flushed from the femurs and tibias of GFP mice using a 25-
guage needle. Mononuclear cells were suspended in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine
serum and plated in flasks. Cultures were maintained at 37C in a hu-
midified atmosphere containing 5% carbon dioxide. After 24 hours,
nonadherent cells were discarded, and adherent cells were washed
three times with phosphate-buffered saline solution (PBS). Fresh
complete medium was added and replaced every 4 days. Each
primary culture was subcultured 1:2 when MSCs grew to approxi-
mately 80% confluence. To confirm the cellular identity of cultured
cells, we subjected MSCs to fluorescence-activated cell sorting
using CD90, CD34, and CD45 markers, and cultured cells were
identified as CD901 and CD342/CD452 cells.
Sublethal Hypoxia Protocol
For HP treatment, cells were subcultured 1:2 and cultured for 3 days
until confluent. Fresh complete medium was added before hypoxia.
Hypoxia treatment was achieved with a well-characterized, finely
controlled ProOx-C-chamber system (Biospherix, Redfield, NY)
for 24 hours. The oxygen concentration in the chamber was main-
tained at 0.5%, with a residual gas mixture composed of 5% carbon
dioxide and balanced nitrogen.
Cell Death Assays in Vitro
Cell death was assayed using trypan blue staining as described
previously.18
Western Blot Analysis
Immunoblot was applied to determine the effect of HP on the
expression of growth factors and antiapoptotic genes in MSCs. Cul-
tured cells were lysed with modified radioimmunoprecipitation
assay buffer (50 mmol/L HEPES, pH 7.3, 1% sodium deoxycholate,
1% Triton X-100, 0.1% sodium dodecylsulfate, 150 mmol/L NaCl, 1
mmol/L ethylenediaminetetraacetic acid, 1mmol/LNa3VO4, 1mmol/
L NaF, and protease inhibitor cocktail [Roche, Nutley, NJ]) for 30
minutes, followed by centrifugation at 14,000g for 30 minutes. Pro-
tein concentration of each sample was determined with the Bicincho-
ninic Acid Assay (SigmaChemical Co, St Louis, Mo). Then, 40 mg of
protein per sample was electrophoresed on a 6%- to 15%-gradient gel
by sodium dodecylsulfate–polyacrylamide gel electrophoresis in
a Hoefer Mini-Gel system (Amersham Biosciences, Piscataway,
NJ) and transferred in a Hoefer Transfer Tank (Amersham Biosci-
ences) to polyvinylidene difluoride membrane (Bio-Rad, Hercules,
Calif). Membranes were blocked with 7%milk in Tris-buffered saline
and 0.2% Tween at room temperature for 2 hours and were then incu-
bated overnight at 4C with specific primary antibodies. The blots
were washed three times with Tris-buffered saline and 0.2% Tween
and incubated with alkaline phosphatase–conjugated secondary anti-
bodies for 2 hours at room temperature. The expression signals were
detected with 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetra-
zolium (BCIP/NBT) solution (Sigma).
Rat Model of MI
Male Wistar rats (280–330 g) were intubated under general anesthe-
sia with 4% chloral hydrate (4 mg/kg, administered intraperitone-
ally) and ventilated with room air by a small animal ventilator
(Vetronics, Lafayette, Ind). MI was induced by permanent ligation
of the left anterior descending coronary artery with a 6–0 silkil 2008
Hu et al Cardiopulmonary Support and Physiology
CS
Psuture.19 Successful performance of coronary occlusion was verified
by blanching of the myocardium distal to the coronary ligation. The
sham-operation group received the same procedure of thoracotomy
without coronary ligation. A minimum of 6 animals was in each
experimental group. In our investigation, the MI-induced mortality
rate was 15%. We did not notice a significant difference between
groups. The investigation conforms to the ‘‘Guide for the Care and
Use of Laboratory Animals’’ published by the USNational Institutes
of Health (NIH Publication No. 85-23, revised 1996).
Cell Preparation and Transplantation
MSCs were labeled with Hoechst 33342 to track and count the
implanted cells. In brief, sterile Hoechst 33342 was added to culture
mediumwith a final concentration of 10 mmol/mL for 2 hours before
transplantation. Then the cells were rinsed 6 times with PBS to
remove unboundHoechst 33342, detached with 0.25% (w/v) trypsin
ethylenediaminetetraacetic acid, and suspended in complete
medium. Cells were centrifuged and washed with PBS, followed
by the final centrifugation and suspension in serum-free medium
at 1 3 106 cells per 150 mL. Before transplantation, MSCs in the
HP group (H-MSCs) were treated for 24 hours with sublethal hyp-
oxia (0.5% oxygen) and then reoxygenated in 20% oxygen for 2
hours. Half an hour after ligation of the left anterior descending
coronary artery, 150 mL of medium containing 1 3 106 cells was
directly injected into the ischemic peri-infarct region. MI control
rats received MI alone and received the same volume of serum
free/cell free medium injection. Experimental groups were divided
into four groups of 10 rats each: (1) MI with transplant of normoxic
MSCs (N-MSCs), (2) MI with transplant of hypoxia-pretreated
MSCs (H-MSCs), (3) MI with injection of control medium, and
(4) sham-operated control group.
Immunofluorescence Staining
For immunofluorescence staining, cells on dishes and in heart tis-
sues were fixed with 10% formalin for 10 minutes, permeabilized
with 0.2%Triton X-100 for 5minutes, and blocked with 1%fish gel-
atin (Sigma) for 1 hour at room temperature. Specimens were then
incubated with primary antibodies overnight at 4C, then washed
with PBS three times, and incubated with Cy3-conjugated donkey
anti-rabbit immunoglobulin G (1:500; Jackson ImmunoResearsh,
West Grove, Pa) or Alexa Fluor 488 anti-goat immunoglobulin G
(1:200, Molecular Probes, Carlsbad, Calif) for 1 hour at room tem-
perature. The cells were treated with Hoechst 33342 (1:20000;
Molecular Probes, Carlsbad, Calif) for 5 minutes. Dishes or slides
were mounted and analyzed under a florescent microscope (BX51,
Olympus, Tokyo, Japan).
Measurement of Hemodynamics
Cardiac hemodynamics was measured at 6 weeks after myocardial
ischemia. Rats were anesthetized with 4% chloral hydrate (40 mg/
kg, intraperitoneally). The carotid artery was isolated and cannu-
lated with a microtip catheter that was connected with an
MLT0699 disposable pressure transducer (ADInstrument, Colorado
Springs, Colo). Left ventricular systolic pressure (LVSP), left ven-
tricular end-diastolic pressure (LVEDP), maximum dp/dt (1dp/dt,
pressure rise rate) and minimum dp/dt (2dp/dt, pressure decrease
rate), and heart rate were monitored and recorded by the Power-
lab/800 data acquisition system (ADInstrument).The Journal of ThoraInfarct Size Measurement
After measurement of hemodynamics, the animals were humanely
sacrificed and the hearts were quickly harvested and divided into
three transverse sections. Tissues from the free wall of the left ven-
tricle including infarct and peri-infarct regions were then embedded
in optimal cutting temperature (OCT) compound (Sakura Finetek
USA Inc, Torrance, Calif). Frozen sections of left ventricular sam-
ples were cut at 10-mm thickness and prepared for staining. To de-
termine infarct size, hearts at papillary muscle level were selected
and Masson trichrome and hematoxylin–eosin staining were per-
formed. Images were digitized by the NIH image analysis system
(National Institutes of Health, Bethesda, Md). Infarct size was calcu-
lated by dividing the sum of the planimetered endocardial and epi-
cardial circumferences of the infarcted area by the sum of the total
epicardial and endocardial circumferences of the left ventricle.20
Terminal Deoxynucleotidyl Transferase Biotin-dUPT
Nick End Labeling (TUNEL) in heart sections
A TUNEL staining kit (DeadEnd Fluorometric TUNEL system,
Promega, Madison, Wis) was used to visualize cell death in heart
sections. After 10 minutes of fixing by 10% buffered formalin phos-
phate (Fisher Scientific, Pittsburgh, Pa) and pretreatment with
220C ethanol/acetic acid (2:1) and 0.2% Triton X-100, the heart
sections were incubated in an equilibration buffer as instructed by
the kit. The TdT enzyme and nucleotide mix was then added at pro-
portions specified by the kit for 75minutes at room temperature. The
slides were washed with 23 standard saline citrate washing buffer
for 15 minutes and followed by three washings with PBS.
Cell and Vessel Counting
Cell count was performed using a design-based stereologic method.
For counting caspase-3 positive cells in cultures, 6 fields per dish
were randomly chosen under 203 magnification of a fluorescent
microscope (n 5 4). For counting caspase-3, Hoechst 33342, and
GFP-positive cells and vessels in heart sections, every tenth heart
section (100 mm apart) across the entire region of interest was
counted, and 6 fields per heart section were randomly chosen and
photographed under 403 magnification with a fluorescent micro-
scope; this was repeated in 4 separate sections per heart.
Statistical Analysis
The Student two-tailed t test was used for comparison of two exper-
imental groups. Multiple comparisons were done by 1-way analysis
of variance followed by the Tukey post hoc test for multiple pairwise
examinations. Data are expressed as the mean 6 standard error of
mean.
Results
Effect of HP on Expression of Pro-survival and
Angiogenic Factors
To characterize the effect of hypoxia on MSCs, we first ana-
lyzed the protein expression levels of growth and angiogenic
factors in N-MSCs and H-MSCs by Western blotting.
N-MSCs displayed endogenous expression of growth and
angiogenic factors including HIF-1a, vascular endothelial
growth factor (VEGF) and its receptor (Flk-1), angiopoie-
tin-1, and erythropoietin (EPO) and its cognate receptorcic and Cardiovascular Surgery c Volume 135, Number 4 801
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CSP(EPOR). As expected, sublethal hypoxia significantly
increased the HIF-1a protein expression level (3.4-fold) as
well as Flk-1, angiopoietin-1, EPO, and EPOR in H-MSCs
(Figure 1).
Consistent with a model of HP as protective to cell sur-
vival, H-MSCs displayed a significant increase in the expres-
sion of pro-survival proteins p105, the nuclear factor-kB
subunits P65 and P50, and anti-apoptotic proteins Bcl-2
and Bcl-xL. Increased nuclear fractions of P65 and P50 fur-
ther suggested activation and translocation of these two
nuclear factor-kB transcription factors (Figure 2). The hyp-
oxia treated cells also had a significantly lower level of active
caspase-3 than did N-MSCs (Figure 2).
HP Promotes Cell Survival In Vitro and After
Transplantation
To determine the vulnerability of N-MSCs and H-MSCs to
apoptosis, we subjected cells in culture to 24 hours of nor-
moxia or sublethal hypoxia followed by 24 hours of serum
Figure 1. Hypoxic preconditioning up-regulated HIF-1a and
growth factor expression. HIF-1a as well as pro-survival and
pro-angiogenic factors Ang-1, VEGF, Flk-1, EPO, and EPOR were
detected by Western blot. A, The expression levels of HIF-1a,
Ang-1, VEGF, Flk-1, EPO, and the EPOR in N-MSCs and H-MSCs.
Mouse b-actin was used as the loading control. B, Densitometry
analysis for comparisons of the relative expression levels of dif-
ferent factors in H-MSCs with respect to N-MSCs (dotted line).
N 5 6. *P < .05 compared with N-MSCs by the Student 2-tailed
t test. HIF-1a, Hypoxia-inducible factor-1a; N-MSC, Normoxic
mesenchymal stem cell; H-MSC; hypoxic mesenchymal stem
cell; Ang-1, angiopoietin-1; VEGF, vascular endothelial growth
factor; EPO, erythropoietin; EPOR, cognate receptor of erythropoi-
etin.802 The Journal of Thoracic and Cardiovascular Surgery c Apdeprivation. Cells were then stained with trypan blue and cas-
pase-3 to assess cell death and apoptosis, respectively. The
hypoxia treatment was confirmed to be sublethal with no sig-
nificant increases in trypan blue (Figure 3) or caspase-3 stain-
ing (data not shown). Serum deprivation increased the ratio
of trypan blue and caspase-3 staining positive cells in both
N-MSCs and H-MSCs; however, the increases were much
less in H-MSCs than in N-MSCs (Figure 3). The percentage
of trypan blue positive cells versus total cells was 24.3% 6
5.4% and 39.3% 6 6.8% in H-MSCs and N-MSCs, respec-
tively (n5 4, P, .05), and the percentage of caspase-3 pos-
itive cells was 25.6%6 5.4%and36.6%6 6.6%, respectively
(n5 4, P , .05) (Figure 3).
To assess whether HP might protect MSCs in vivo, we
transplanted N-MSCs and H-MSCs into the peri-infarcted
region 30 minutes after MI. Twenty-four hours later, the
animals were humanely sacrificed and apoptosis of implanted
cells was identified by the ratio of caspase-3/Hoechst/GFP
co-labeled cells versus total transplanted cells pre-labeled
with Hoechst and GFP; cell death was identified by the ratio
of TUNEL/Hoechst positive cells versus total transplanted
cells. In the H-MSC transplantation group, the implanted
cell death and apoptosis-associated caspase-3 activation
were significantly suppressed (Figure 4). To test whether
HP might prevent delayed MSC cell death, we assessed
cell death using TUNEL staining 72 hours after transplanta-
tion. In the H-MSC transplantation group, the ratio of
TUNEL positive cells was significantly reduced (Figure 4).
Enhanced Angiogenesis/Vascularization After MSC
Transplantation
To assess angiogenic and vascularization activity, we stained
heart sections with the endothelial cell marker CD31 and ar-
teriole marker smooth muscle actin. Six weeks after ischemia
with or without MSC transplantation, both the total vessel
density/area and arteriole density/area in both MSC trans-
plantation groups were greater than those in the ischemia-
only group (Figure 5). Between the two transplantation
groups, significantly greater total vessel density/area and
arteriole density/area were observed in the H-MSC group
than in the N-MSC group (n 5 6 rats per group, P , .05)
(Figure 5). To further clarify whether HP promoted endothe-
lial cell differentiation of MSCs, we calculated the ratio of
CD31/Hoechst positive cells versus total transplanted cells
pre-labeled with Hoechst. A higher endothelial cell differen-
tiation ratio was identified in the H-MSC transplantation
group than in the N-MSC group (n5 6, P, .05) (Figure 5).
Possible Myogenesis From Transplanted MSCs
Myosin heavy chain staining showed that few MSCs
expressed the myocyte protein myosin heavy chain in trans-
planted heart 6 weeks after transplantation (Figure 5). Our
data, however, could not rule out the possibility that the
co-labeling was due to cell fusion between exogenous andril 2008
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PFigure 2. Effect of hypoxic preconditioning on
anti-apoptotic gene expression. Western blot
analysis of several key factors in cell survival,
apoptosis and angiogenesis in N-MSCs and H-
MSCs. A and B, Expression of NF-kB precursor
P105, subunit P65, and P50 in cell lysate (A) and
nuclear fraction (B). Mouse b-actin was used as
the loading control. C, Densitometry analysis for
comparisons of expression ratios of NF-k B sig-
nals in H-MSCs with respect to the basal levels
in N-MSCs (dotted line). D, Protein levels of Bcl-
2, Bcl-xL, and cleaved caspase-3 detected by
Western blot. E, Densitometry of Bcl-2, Bcl-xL,
and caspase-3 expression in H-MSCs compared
with that in N-MSCs (dotted line). *P < .05 com-
pared with N-MSCs by the Student 2-tailed t
test. For abbreviations, see Figure 1.host cells.6,7 We also did not identify a noticeable effect of
HP on this potential myogenesis.
MSC Transplantation Reduces Infarct Size
Hematoxylin–eosin staining and Masson trichrome staining
of cardiac tissue revealed fibrosis in the infarct region 6
weeks after ischemia. Scar formation was evident in the
ischemic hearts that received a medium control injection
(Figure 6). The infarct size was reduced in both groups that
received MSC transplantation; however, rats receiving
H-MSC transplantation showed the smallest infarct size
(Figure 6).
Transplantation of MSCs improves cardiac function
Six weeks after ischemia, functional recovery of ischemic
heart was measured by the LVSP, LVEDP, 1dp/dt, and
2dp/dt. MSC transplantation helped to prevent negative
left ventricular remodeling. Rats that received N-MSCs had
significantly increased LVSP and absolute values of 6dp/
dt compared with the control group (Figure 6). Even greater
cardiac functional benefits were found in H-MSC transplan-The Journal of Thtation group, showing higher LVSP, improved 6dp/dt, and
near normal LVEDP (Figure 6).
Discussion
The present study explored a novel preconditioning strategy
to enhance the ability of MSCs to survive under pathologic
conditions and promote their therapeutic effects within the is-
chemic heart. We have shown that sublethal hypoxia induces
increases in several pro-survival and pro-angiogenic factors
within the MSCs, contributing to the enhanced tolerance of
H-MSCs to apoptosis and increased angiogenesis after trans-
plantation. Uemura and associates21 recently reported that
transplantation of hypoxic preconditioned MSCs reduced
the apoptosis of cardiomyocytes. In the present investigation,
we provide new evidence that transplantation of hypoxic
preconditioned MSCs promotes heart functional recovery
through enhancing implanted cell survival and angiogenesis
after MI.
Previous studies have shown that allogeneic MSCs are
immunoregulatory and do not induce immune response
in vitro22 and in vivo23; xenogeneic bone marrow stromaloracic and Cardiovascular Surgery c Volume 135, Number 4 803
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CSPFigure 3. Effect of hypoxic precondi-
tioning on cell death and cell survival
in vitro. GFP MSC nuclei were pre-
stained with Hoechst 33342 (blue); the
double labeling of GFP and nuclear
stain facilitated cell counting of MSCs.
Cell apoptosis was identified by the
antibody against the cleaved/activated
caspase-3 (red). A–I, Activated cas-
pase-3 (arrow) staining in control,
N-MSCs and H-MSCs subjected to 24-
hour SD. Bar5 50 mm. J and K, Summa-
rized data of caspase-3 activation for
apoptosis (J) and trypan blue staining
for cell death (K). The ratio of cell apo-
ptosis and cell death were significantly
increased after SD, and hypoxic pre-
conditioning significantly reduced apo-
ptosis. N 5 4. *P < .05 compared with
N-MSCs plus SD. GFP, Green fluores-
cent protein; SD, serum deprivation;
for other abbreviations, see Figure 1.cells transplanted into ischemic myocardium were immuno-
logically tolerant and feasible.24 Therefore, immunosuppres-
sion was not given in the present investigation and no
rejection of implanted cells was noticed. Transplanted bone
marrow MSCs are sensitive to ischemic and inflammatory
microenvironment as is evidenced by stem cell death that
often occurs soon after transplantation.6,8,25 This cell death
may, in turn, increase the inflammatory response and be an
additional burden to the ischemic heart, hindering functional
recovery. Genemodification has been investigated to enhance
stem cell survival and efficiency of cell transplantation ther-
apy. For instance, overexpression of Akt can reduce apoptosis
of MSCs and then enhance the heart functional improve-
ment.26 Our previous study showed that transplantation of
embryonic stem cells overexpressing Bcl-2 increased the sur-
vival and neuronal differentiation of transplanted cells, aswell
as functional recovery after cerebral ischemic stroke.27804 The Journal of Thoracic and Cardiovascular Surgery c ApWhether or not permanent gene modification has a long-
term risk of tumorigenesis is not clear,28 which may limit its
clinical utility. On the basis of this concern, increasing
attention has been paid to short but comprehensive improve-
ments of the quality of transplanted cells. The present study
supports that HP may be explored as such a strategy in cell
transplantation therapy for ischemic heart diseases.
Considering that up to 90% of grafted cells may die within
the first few days of transplantation, the transient cytoprotec-
tive effect of HP should be sufficient to protect transplanted
cells during the initial critical period after transplantation. En-
hanced implanted cell survival can reduce the required num-
ber of transplanted cells, and fewer stem cells may actually
differentiate better. Transplantation of MSC was performed
30 minutes after MI. In this case, some observed beneficial
effects might result from myocardial rescue that prevented
negative remodeling during the acute phase. Therapeuticril 2008
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PFigure 4. Effect of hypoxic precondi-
tioning on implanted cell death 1 to 3
days after myocardial infarction. MSCs
were labeled with Hoechst 33342
(blue) before transplantation. Cell apo-
ptosis was identified with activated
caspase-3, cell death was identified
with TUNEL staining. A and B, Co-label-
ing of activated caspase-3 (red) and
Hoechst (blue arrows) indicates apo-
ptosis of graft cells in the ischemic
heart 24 hours after myocardial infarc-
tion. C and D, Merged images of cas-
pase-3/Hoechst/GFP that further
confirmed the apoptosis of implanted
cells. E and F, Co-labeling of TUNEL
(red) and Hoechst (blue) 24 hours after
myocardial infarction in N-MSC and H-
MSC transplantation group, respec-
tively. G and H, Co-labeling of TUNEL
and Hoechst 72 hours after myocardial
infarction. Bar 5 20 mm. I and J, Sum-
marized data of caspase-3 activation
for apoptosis (I) and TUNEL staining
for cell death (J). Hypoxic precondition-
ing significantly reduced cell death and
apoptosis of transplanted MSCs in the
ischemic heart. *P < .05 compared
with N-MSC. TUNEL, Terminal deoxynu-
cleotidyl transferase biotin-dUPT nick
end labeling. For other abbreviations,
see Figure 1.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 4 805
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CSPFigure 5. Differentiation of transplanted
cells in ischemic heart 6 weeks after
MI. Immunohistochemical staining of
heart sections at transplanted sites af-
ter MI and transplantation. MSCs were
labeled with Hoechst 33342 before
transplantation, and vascular endothe-
lial cells were stained with CD31, arte-
riole marker was stained with SMA and
cardiomycyte marker was stained with
myosin heavy chain. A, Three-dimen-
sional image shows a vascular-like
structure positively labeled with
Hoechst (blue) and CD31 (red). Bar 5
40 mm. B, Three-dimensional image of
Hoechst/MHC and GFP (green), indicat-
ing some graft cells develop into car-
diac-like myocytes. Bar 5 10 mm. C–E,
Merged images of Hoechst and CD31
(red) staining in three experimental
groups; F–H, Merged images of Hoechst
33342 and SMA (red) staining in three
experimental groups; increased num-
bers of CD31-positive vessels and
SMA-positive arterioles were seen in
the MSC transplantation groups. Bar 5
40mm. I–K, Summary of total vessel den-
sity and arteriole density (I), area per
field (J) and endothelial differentiation
ratio (K) in three experimental groups.
Angiogenic and/or vasculogenic activi-
ties were enhanced in the MSC trans-
plantation rats; H-MSCs showed
stronger angiogenic potency compared
with N-MSCs. N5 6. *P< .05 compared
with MI group. #P < .05 compared with
N-MSC group. MI, Myocardial infarc-
tion; SMA, smooth muscle actin. For
other abbreviations, see Figure 1.fi
s
a
T
epotential of transplantation of MSCs in the chronic phase
long after MI remains to be examined. MSCs may provide
host tissues and themselves with trophic support. MSCs
can express cytokines and growth factors that play important
roles in cell survival and angiogenesis, such as VEGF, basic806 The Journal of Thoracic and Cardiovascular Surgery c Aprilbroblast growth factor, angiopoietin-1, and EPO.12,29 Our
tudy demonstrates that MSCs express these factors, which
re up-regulated by HP, in line with previous studies.21,30
hese growth factors exert both autocrine and paracrine
ffects. HP augmented paracrine signaling and reduced2008
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PFigure 6. MSC transplantation reduced
MI-induced infarct size and improved
heart function. A–C, Masson trichrome
staining reveals infarct and scar forma-
tion 6 weeks after MI. N-MSC trans-
plantation inhibited the infarct size
compared with the MI-only group (B).
The smallest infarct size was seen in
the H-MSC transplantation group (C).
D, Summary of infarct size in three
experimental groups. E, LVSP de-
creased significantly 6 weeks after MI
compared with sham group. While
MSC transplantation improved LVSP, H-
MSC transplantation showed stronger
effect on LVSP recovery. F, LVEDP in-
creased markedly 6 weeks after MI;
N-MSC transplantation showed no sig-
nificant effect while H-MSC transplan-
tation enhanced LVEDP to a near
normal level. G and H, Left ventricular
1dp/dt (G) and 2dp/dt (H) decreased 6
weeks after MI; both transplantation
groups increased 6dp/dt, especially in
the H-MSC transplantation group. N 5
6. *P < .05 as compared with the MI-
only group. #P < .05 as compared with
N-MSC transplantation group. MSC,
Mesenchymal stem cell (N, normoxic;
H, hypoxic); MI, myocardial infarction;
LVSP, left ventricular systolic pressure;
LVEDP, left ventricular end-diastolic
pressure; dp/dt, rate of pressure rise.The Journal of Tholial differentiation of bone marrow stem cells, which together
contributed to improved angiogenesis in the ischemic hind
limb after transplantation.33 Our finding that HP increased
vessel density, area, and the endothelial cell differentiation
ratio is consistent with this previous study. The higher vessel
density in H-MSC transplantation group is attributable to
both enhanced paracrine effect and increased endothelial
cell differentiation. Several groups have reported that
MSCs can differentiate into cardiomyocytes9,34; other studies
question the possibility that MSCs might fuse with host cells
after transplantation into the ischemic heart.6,7 Our study
identified that, 6 weeks after transplantation, a few MSCs
showed characteristic myosin protein expression. Whether
transplanted MSCs may undergo cardiac myocyte differenti-
ation is under debate. Moreover, possible fusion and uptake
of Hoechst dye by endogenous cells might also affect the en-
dothelial cell counts. In any event, transplanted MSCs helped
to repair infarcted myocardium, disregarding the rare events
of myogenesis or cell fusion.35
In conclusion, our study demonstrates that transplanta-
tion of HP-treated MSCs shows better therapeutic effects
in the ischemic heart. The functional benefit of H-MSCcardiomyocytes apoptosis.21,30 Several transcription factors
may be involved in the response to hypoxia, such as activated
protein-1, HIF-1a, and nuclear factor-kB.31 Activation of
some growth factor pathways can activate nuclear factor-kB
and increase the survival genes such as Bcl-2 and Bcl-xL.32
Consistent with these anti-apoptotic effects, caspase-3 activa-
tion is suppressed inH-MSCs. It is likely that a combination of
these multiple mechanisms is responsible for the increased
viability of H-MSCs.
In this study, MI-induced animal death mostly occurred
3 days after surgery, which was not affected by H-MSC
transplantation. The lack of the effect on animal mortality
suggests that although the hypoxic preconditioned MSCs
survives better in the ischemic heart, the increased cell sur-
vival is not sufficient to antagonize the initial overwhelming
insults and functional failure in the acute phase of MI.
Moreover, the H-MSC–promoted cell survival and angio-
genesis are expected to primarily benefit long-term tissue
repair and function recovery many days after MI, as shown
in this investigation.
An earlier study showed that ex vivo HP up-regulated the
synthesis of VEGF messenger RNA and stimulated endothe-racic and Cardiovascular Surgery c Volume 135, Number 4 807
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CSPtransplantation might be explained by several possibilities:
(1) HP enhances the autocrine and paracrine signaling of
MSCs, which reduces apoptosis of transplanted cells and
endogenous cardiomyocytes; (2) the increased survival of
H-MSCs provides better and longer trophic support for
the reparative process; (3) the increase in survival of en-
grafted cells contributes to increased angiogenesis. These
factors collectively promote tissue repair and may provide
a simple but effective new strategy for clinical MSC trans-
plantation therapy. Of note, although HP of MSCs may
show the above benefits, transplantation of H-MSCs did
not improve short-term animal survival 3 days after MI;
its effect on long-term mortality remains to be tested.
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